Emneord (Nøkkelord)
obstetric cholestasis
hematological inflammatory markers
ICP
Hvordan referere
Sammendrag
Introduction Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder associated with elevated bile acid levels, systemic inflammation, and increased maternal and fetal risks. Identifying accessible and cost-effective inflammatory biomarkers may improve clinical assessment of patients with ICP.
Materials and methods The case-control study included 142 pregnant women: 71 diagnosed with ICP and 71 healthy controls. Hematological inflammatory markers were evaluated, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), red cell distribution width (RDW), and emerging ratios such as platelet-to-monocyte ratio (PMR) and C-reactive protein-to-lymphocyte ratio (CLR). Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis.
Results NLR and PLR were significantly higher in the ICP group than in the control group (p<0.0001). ROC analysis demonstrated moderate discriminatory ability for NLR (AUC=0.707) and PLR (AUC=0.709). Other markers showed limited diagnostic value.
Conclusions NLR and PLR provide additional information regarding systemic inflammation in patients with ICP and may serve as complementary tools in clinical evaluation. Further studies are required to confirm their prognostic and diagnostic relevance.
Referanser
1. Girling J, Knight CL, Chappell L. Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43. BJOG. 2022;129(13):e95-e114. https://doi.org/10.1111/1471-0528.1720.
2. Hobson SR, Cohen ER, Gandhi S, et al. Guideline No. 452: Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy. J Obstet Gynaecol Can. 2024;46(8):102618. https://doi.org/10.1016/j.jogc.2024.102618.
3. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Lee RH, Mara Greenberg, Metz TD, Pettker CM. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am J Obstet Gynecol. 2021;224(2):B2-B9. https://doi.org/10.1016/j.ajog.2020.11.002.
4. Hague W.M, Briley A, Callaway L., Dekker Niter M, Gehlert J, Graham D, Grzeskowiak L, Makris A, Markus C, Middleton P, Peek M.J, Shand A, Stark M. and Waugh J. Intrahepatic cholestasis of pregnancy – Diagnosis and management: A consensus statement of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ): Executive summary. Aust N Z J Obstet Gynaecol. 2023:63: 656-665. https://doi.org/10.1111/ajo.13719.
5. Yu X, Yang H, Qi H. Clinical Management Guidelines for Intrahepatic Cholestasis of Pregnancy. Matern Fetal Med. 2024;6(1):13-22. Published 2024 Jan 10. https://doi.org/10.1097/FM9.0000000000000207.
6. Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899-909. https://doi.org/10.1016/S0140-6736(18)31877-4.
7. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;7;15(17):2049-66. https://doi.org/10.3748/wjg.15.2049.
8. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014;124(1):120-133. https://doi.org/10.1097/AOG.0000000000000346.
9. Zhou Q, Yuan Y, Wang Y, et al. The severity of intrahepatic cholestasis during pregnancy increases risks of adverse outcomes beyond stillbirth: evidence from 15,826 patients. BMC Pregnancy Childbirth. 2024;24(1):476. Published 2024 Jul 12. https://doi.org/10.1186/s12884-024-06645-2.
10. Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394(10201):849-860. https://doi.org/10.1016/S0140-6736(19)31270-X.
11. Ovadia C, Sajous J, Seed PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(7):547-558. https://doi.org/10.1016/S2468-1253(21)00074-1.
12. Xiao J, Li Z, Song Y, et al. Molecular Pathogenesis of Intrahepatic Cholestasis of Pregnancy. Can J Gastroenterol Hepatol. 2021;2021:6679322. https://doi.org/10.1155/2021/6679322.
13. Tang B, Tang L, Li S. et al. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy. Nat Commun 14, 1305 (2023). https://doi.org/10.1038/s41467-023-36981-4.
14. Dixon PH, van Mil SW, Chambers J, et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut. 2009;58(4):537-544. https://doi.org/10.1136/gut.2008.159541.
15. Zöllner J, Williamson C, Dixon PH. Genetic issues in ICP. Obstet Med. 2024. https://doi.org/10.1177/1753495X241263441.
16. Cemortan M., Cernetchi O. Assessment of the role of hematological inflammatory markers in the severity of intrahepatic cholestasis of pregnancy. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 2(28), pp. 19-24. ISSN 2345-1467. https://doi.org/10.52645/MJHS.2022.2.03.
17. Zhang D, Li Y, He S. et al. Association between ABCB4 variants and intrahepatic cholestasis of pregnancy. Sci Rep 15, 3300 (2025). https://doi.org/10.1038/s41598-025-87909-5.
18. Hantoushzadeh S, Gargar OK, Jafarabady K, et al. Diagnostic value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio to predict recurrent pregnancy loss and abortion; a systematic review and meta-analysis. Immun Inflamm Dis. 2024;12(3):e1210. https://doi.org/10.1002/iid3.1210.
19. Çallıoğlu N, Tuna G, Tandoğan Ö, Ersan F, Atalay S, Bilirer KK. Systemic immune-inflammatory index and platelet-to-lymphocyte ratio in intrahepatic cholestasis of pregnancy. Saudi Med J. 2024;45(11):1217-1222. https://doi.org/10.15537/smj.2024.45.11.20240760.
20. Obut M, Kından A, Ibanoğlu MC, et al. Liver damage parameters and peripheral blood parameters for prediction and diagnosis of intrahepatic cholestasis in pregnancy. J Obstet Gynaecol Res. 2024;50(2):196-204. https://doi.org/10.1111/jog.15837.
21. Ji D, et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio in Intrahepatic Cholestasis of Pregnancy. 2025. https://doi.org/10.12968/hmed.2024.0543.
22. Gunenc O, Sarikaya S, Korez MK. The value of hematological parameters measured at first presentation in patients diagnosed with pregnancy in predicting early pregnancy loss; can NLPR be a new predictive value? A case-control study. J Matern Fetal Neonatal Med. 2025;38(1):2525399. https://doi.org/10.1080/14767058.2025.2525399.
23. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474-488. https://doi.org/10.4149/BLL_2021_078.
24. Morisaki N, Piedvache, A, Nagata C. et al. Maternal blood count parameters of chronic inflammation by gestational age and their associations with risk of preterm delivery in the Japan Environment and Children’s Study. Sci Rep 11, 15522 (2021). https://doi.org/10.1038/s41598-021-93101-2.
25. Mészáros B, Veres DS, Nagyistók L, Kovács BG, Kukor Z and Valent S (2024) A meta-analysis on first-trimester blood count parameters—is the neutrophil-to-lymphocyte ratio a potentially novel method for first-trimester preeclampsia screening?. Front. Med. 11:1336764. https://doi.org/10.3389/fmed.2024.1336764.
26. Rezaeian S, Razmjooei F, Pourmokhtari M, Abdoli A, Jahromi MA, Bagheri K,. Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19. Heliyon. 2023: (12):e22896. https://doi.org/10.1016/j.heliyon.2023.e22896.
27. Targońska-Stępniak B, Zwolak R, Piotrowski M, Grzechnik K, Majdan M. The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis. J Clin Med. 2020;9(9):2760. https://doi.org/10.3390/jcm9092760.
28. Lyakhovitsky A., Dascalu J. et al. Hematological Inflammatory Markers in Patients with Pemphigus Vulgaris. Dermatology. 2021;237(6): 912–920. https://doi.org/10.1159/000512916.
29. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. Dis Markers. 2017;2017:3041565. https://doi.org/10.1155/2017/3041565.
30. Karabay G, Bayraktar B, Seyhanli Z. et al. Predictive value of inflammatory markers (NLR, PLR, MLR, SII, SIRI, PIV, IG, and MII) for latency period in Preterm premature rupture of membranes (PPROM) pregnancies. BMC Pregnancy Childbirth. 564:2024. https://doi.org/10.1186/s12884-024-06756-w.
31. Çallıoğlu N, Gül DK, Arslan İÖ, Geyikoğlu İ, Demirçivi E. Inflammatory markers in systemic immune-inflammatory index and inflammatory response index to predict early pregnancy loss. Saudi Med J. 2024;45(8):808-813. https://doi.org/10.15537/smj.2024.45.8.20240404.
32. Bozbay N, Medinaeva A, Akyürek F, Orgul G. The role of first-trimester systemic immune-inflammation index for the prediction of gestational diabetes mellitus. Rev Assoc Med Bras (1992). 2024;70(10):e20240532. Published 2024 Sep 30. https://doi.org/10.1590/1806-9282.20240532
33. Liu K, Tang S, Liu C, et al. Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Front Immunol. 2024;15:1337241. https://doi.org/10.3389/fimmu.2024.1337241.
34. Zhidan Z, Jianhua L, et al. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection. International Immunopharmacology. 51;2017:1-8. https://doi.org/10.1016/j.intimp.2017.07.007.
35. Minici R., Siciliano MA., Ammendola M., et all. Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers. 2023;15(1):257. https://doi.org/10.3390/cancers15010257.
36. Seyhanli Z, Bayraktar B, Baysoz OB, et al. The role of first trimester serum inflammatory indexes (NLR, PLR, MLR, SII, SIRI, and PIV) and the β-hCG to PAPP-A ratio in predicting preeclampsia. J Reprod Immunol. 2024;162:104190. https://doi.org/10.1016/j.jri.2023.104190.
37. Hai, L., & Hu, Z. The clinical utility of neutrophil to lymphocyte ratio in pregnancy related complications: a mini-review. Journal Of Laboratory And Precision Medicine. 2019(5). https://doi.org/10.21037/jlpm.2019.10.03.
38. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653-657. https://doi.org/10.1016/j.amjcard.2008.05.006.
39. Ovadia C, Williamson C. Intrahepatic cholestasis of pregnancy: Recent advances. Clin Dermatol. 2016;34(3):327-334. https://doi.org/10.1016/j.clindermatol.2016.02.004.
40. Stafford,D.W. The vitamin K cycle. Journal of Thrombosis and Haemostasis. 2005;3(8):1873-1878. https://doi.org/10.1111/j.1538-7836.2005.01419.x.
41. Smith DD., Rood KM. Intrahepatic Cholestasis of Pregnancy. Clin Obstet Gynecol. 2020;63(1):134-151. https://doi.org/10.1097/GRF.0000000000000495.
42. Cemortan M, Sagaidac I, Cernetchi O. Assessment of vitamin K levels in women with intrahepatic cholestasis of pregnancy. BMC Pregnancy Childbirth. 2022;22(1):534. https://doi.org/10.1186/s12884-022-04875-w.
43. Obut M, et al. Liver damage parameters and peripheral blood inflammatory markers for prediction and diagnosis of intrahepatic cholestasis of pregnancy. 2024. Direct source: https://pubmed.ncbi.nlm.nih.gov/37994385/.
44. Shen C, et al. Analysis of changes in platelet parameters and blood-derived inflammatory markers around the onset of intrahepatic cholestasis of pregnancy. 2024. Direct source: https://pubmed.ncbi.nlm.nih.gov/39822511/.
45. Arthuis C, Diguisto C, Lorphelin H, et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study. PLoS One. 2020;15(2):e0228213. https://doi.org/10.1371/journal.pone.0228213.
46. Eremina E, Masharova A. Vnutripechenochnyi kholestaz u beremennykh [Intrahepatic cholestasis in pregnant women]. Eksperimental'naia i Klinicheskaia Gastroenterologiia. 2011;(6):87-91.
47. Yuce E, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prediction of spontaneous preterm birth. J Inflamm Res. 2023. https://doi.org/10.2147/JIR.S414305.
48. Qiang T, Ding X, Ling J, & Fei M.. Is platelet to lymphocyte ratio predictive of preeclampsia? A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology, 2023, 43(2). https://doi.org/10.1080/01443615.2023.2286319.
49. Cui H.X., Chen C., Jung Y.M. et al. Neutrophil-to-lymphocyte ratio (NLR) as a predictive index for liver and coagulation dysfunction in preeclampsia patients. BMC Pregnancy Childbirth. 2023;4. https://doi.org/10.1186/s12884-022-05335-1.
50. Kapci M, Sener K, Cakir A, et al. Prognostic value of systemic immune-inflammation index in the diagnosis of preeclampsia. Heliyon, 2024;10. https://doi.org/10.1016/j.heliyon.2024.e28181.
Dette verket er lisensiert under Creative Commons Attribution 4.0 International License.
Opphavsrett 2026 Maria CEMORTAN, Irina SAGAIDAC, Olga CERNETCHI